Drug patent listing and exclusivity clarified in new US bill
The Orange Book Transparency Act of 2020 (H.R. 1503) was signed into law last January 5, 2021. The Act updates regulations of the US Food and Drug Administration concerning the Approved Drug Products with Therapeutic Equivalence Evaluations (more commonly known as the Orange Book) which contains publicly available patent and exclusivity information, particularly on approved and available generic drugs.
US denied dismissal of contract breach claims in Gilead patent dispute
An interesting corner of the growing world of AI is its adoption in the automotive industry. As automakers are racing to develop driverless vehicles for widespread adoption, they recognize that leveraging AI-powered solutions and features will be the key differentiators for their brand.
